Amarogentin
(Synonyms: 苦龙胆酯苷) 目录号 : GC42776
Amarogentin是一种Swertia和Gentiana植物根中提取的裂环烯醚萜苷类天然产物,Amarogentin具有多种生物学活性,包括免疫调节、抗糖尿病和抗肿瘤。
Cas No.:21018-84-8
Sample solution is provided at 25 µL, 10mM.
Amarogentin is a secoiridoid glycoside natural product extracted from the roots of Swertia and Gentiana plants. Amarogentin possesses a range of biological activities, including immunomodulatory, antidiabetic, and antitumor effects[1-2]. Amarogentin has demonstrated potential value in research areas such as gastric cancer, colorectal cancer, diabetes, and neuroprotection[3-4].
In vitro, pretreatment of PC12 cells with Amarogentin (1-10µM) for 24 hours, followed by culture under oxidative stress conditions induced by hydrogen peroxide (0.9mM), Amarogentin significantly inhibited the increase in reactive oxygen species (ROS) and malondialdehyde (MDA) levels caused by oxidative stress. Amarogentin upregulated the gene expression of SOD2, CAT, GPx, Nrf2, and Bcl-x1 while enhancing SOD2 enzymatic activity, thereby exerting a neuroprotective effect[5]. HepG2 and Huh7 cells treated with incomplete radiofrequency ablation (IRFA) were incubated with Amarogentin (120μg/ml) for 24 hours. Amarogentin significantly reduced the proportion of CD133‑positive cells and the secretion of vascular endothelial growth factor A (VEGFA), and inhibited the VEGFA/Dll4/Notch1 signaling pathway via a p53‑dependent mechanism, thereby suppressing angiogenesis[6].
In vivo, oral administration of Amarogentin (50 or 100mg/kg/day) to ovariectomy-induced estrogen-deficient osteoporotic rats for 5 consecutive weeks, Amarogentin significantly increased whole-body and lumbar spine bone mineral density, improved levels of serum bone formation markers (osteocalcin, C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen, and bone-specific alkaline phosphatase), Amarogentin reduced the expression of inflammatory cytokines (IL-1β, IL-17, and TNF-α), and enhanced osteoblast differentiation by modulating the Nrf-2/MAPK/ERK signaling pathway[7]. Intravenous administration of Amarogentin (0.5mg/kg/day; for 1 consecutive week) to streptozotocin-induced type 1 diabetic rats, Amarogentin significantly lowered fasting blood glucose, increased skeletal muscle glucose transporter 4 (GLUT4) expression, and inhibited liver phosphoenolpyruvate carboxykinase (PEPCK) activity[8].
References:
[1] Singh S, Varshney M, Sharma H. Amarogentin, Natural Bitter Terpenoids: Research Update with Pharmacological Potential, Patent and Toxicity Aspects. Curr Top Med Chem. 2025 Aug 21.
[2] Patel K, Kumar V, Verma A, et al. Amarogentin as Topical Anticancer and Anti-Infective Potential: Scope of Lipid Based Vesicular in its Effective Delivery. Recent Pat Antiinfect Drug Discov. 2019;14(1):7-15.
[3] Wölfle U, Haarhaus B, Schempp CM. Amarogentin Displays Immunomodulatory Effects in Human Mast Cells and Keratinocytes. Mediators Inflamm. 2015;2015:630128.
[4] Sur S, Pal D, Banerjee K, et al. Amarogentin regulates self renewal pathways to restrict liver carcinogenesis in experimental mouse model. Mol Carcinog. 2016 Jul;55(7):1138-49.
[5] Disasa D, Cheng L, Manzoor M, et al. Amarogentin from Gentiana rigescens Franch Exhibits Antiaging and Neuroprotective Effects through Antioxidative Stress. Oxid Med Cell Longev. 2020 Aug 1;2020:3184019.
[6] Zhang Y, Zhang Y, Wang J, et al. Amarogentin Inhibits Liver Cancer Cell Angiogenesis after Insufficient Radiofrequency Ablation via Affecting Stemness and the p53-Dependent VEGFA/Dll4/Notch1 Pathway. Biomed Res Int. 2020 Oct 20;2020:5391058.
[7] Li S, Li X, He F, et al. Amarogentin promotes osteoblast differentiation in oestrogen-deficiency-induced osteoporosis rats by modulating the Nrf-2/MAPK/ERK signalling pathway. Arch Med Sci. 2019 Nov 11;19(2):452-457.
[8] Niu HS, Chao PC, Ku PM, et al. Amarogentin ameliorates diabetic disorders in animal models. Naunyn Schmiedebergs Arch Pharmacol. 2016 Nov;389(11):1215-1223.
Amarogentin是一种Swertia和Gentiana植物根中提取的裂环烯醚萜苷类天然产物,Amarogentin具有多种生物学活性,包括免疫调节、抗糖尿病和抗肿瘤[1-2]。Amarogentin在胃癌、结直肠癌、糖尿病以及神经保护的相关研究中显示出潜在的应用价值[3-4]。
在体外,Amarogentin(1-10μM)预处理PC12细胞24小时,随后在过氧化氢(0.9mM)诱导的氧化应激条件下培养,Amarogentin显著抑制氧化应激诱导的活性氧(ROS)和丙二醛(MDA)水平升高,并上调SOD2、CAT、GPx、Nrf2和Bcl-x1的基因表达,同时增强SOD2酶活性,发挥神经保护作用[5]。取经不完全射频消融(IRFA)处理的HepG2和Huh7细胞,使用Amarogentin(120μg/ml)孵育24小时,Amarogentin显著降低CD133阳性细胞比例和血管内皮生长因子A(VEGFA)的分泌,并通过p53依赖性途径抑制VEGFA/Dll4/Notch1信号通路,从而抑制血管生成[6]。
在体内,Amarogentin(50或100mg/kg/day)口服处理双侧卵巢切除诱导的雌激素缺乏性骨质疏松大鼠,连续5周,Amarogentin显著提高全身和腰椎骨密度,改善血清骨形成标志物(骨钙素、I型胶原C端肽、I型前胶原N端前肽和骨特异性碱性磷酸酶)水平,降低炎症因子(IL-1β、IL-17和TNF-α)表达,并通过调节Nrf-2/MAPK/ERK信号通路增强成骨细胞分化[7]。Amarogentin(0.5mg/kg/day;连续1周)静脉注射处理链脲佐菌素诱导的1型糖尿病大鼠,Amarogentin显著降低空腹血糖,增加骨骼肌葡萄糖转运蛋白4(GLUT4)表达,抑制肝脏磷酸烯醇式丙酮酸羧激酶(PEPCK)活性[8]。
| Cell experiment [1]: | |
Cell lines | PC12 cells (rat pheochromocytoma cell line) |
Preparation Method | PC12 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 7.5% fetal bovine serum (FBS) and 10% horse serum at 37°C, 5% CO₂. PC12 cells were pretreated with Amarogentin (1, 3, and 10μM) for 24 hours, followed by oxidative stress induction with 0.9mM H₂O₂ for 1 hour. |
Reaction Conditions | 1–10μM; pretreatment for 24 hours. |
Applications | In PC12 cells, Amarogentin (3μM) reduced H₂O₂-induced reactive oxygen species (ROS) and malondialdehyde (MDA) levels, respectively, while increasing SOD2 activity and gene expression of SOD2, CAT, GPx, Nrf2, and Bcl-x1. |
| Animal experiment [2]: | |
Animal models | Female Sprague-Dawley rats with bilateral ovariectomy (OVX)-induced osteoporosis |
Preparation Method | Osteoporosis was induced via bilateral ovariectomy. Rats were orally administered Amarogentin (50 or 100mg/kg) daily for 5 weeks. Bone mineral density (BMD) and serum biochemical markers were measured post-treatment. |
Dosage form | 50 or 100mg/kg; p.o.; Once daily for 5 weeks. |
Applications | Amarogentin (100mg/kg) significantly increased BMD in the whole body, lumbar spine, and femur of OVX rats compared to untreated OVX controls. Amarogentin attenuated serum levels of bone resorption markers (CTX) and enhanced bone formation markers (osteocalcin, PINP, and BSAP). Amarogentin reduced pro-inflammatory cytokines (IL-1β, IL-17, and TNF-α) in serum and modulated bone tissue expression of Akt, Nrf-2, ERK, and NF-κB p65 proteins. |
References: | |
| Cas No. | 21018-84-8 | SDF | |
| 别名 | 苦龙胆酯苷 | ||
| Canonical SMILES | O=C1OCC[C@]2([H])C1=CO[C@@H](O[C@]3([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3OC(C4=C(C5=CC=CC(O)=C5)C=C(O)C=C4O)=O)[C@@H]2C=C | ||
| 分子式 | C29H30O13 | 分子量 | 586.5 |
| 溶解度 | DMSO: 100 mg/ml,PBS (pH 7.2): 0.1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.705 mL | 8.5251 mL | 17.0503 mL |
| 5 mM | 341 μL | 1.705 mL | 3.4101 mL |
| 10 mM | 170.5 μL | 852.5 μL | 1.705 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















